EurekaMag
+ Translate
+ Most Popular
Sobre os generos Lopadusa Stal e Bothrocoris Mayr (Hemiptera, Pentatomidae, Pentatomini)
RFEF pilot plant for inactivation of Escherichia coli in apple juice
Calpionella alpina Lorenz als "Leitfossil"
Sooretama: The Atlantic Rain Forest of Brazil. Francis Dov Por
Novel approaches in myeloma therapy
Preliminary Notes on the Study of Mitochondria During the 1st Stages of the Destruction of Cadavers
A preliminary study of the biology of lichee stink bug, Tessaratoma papulosa Drury, and its control
The status of the Sabu Island python - Die Situation des Savu-Pythons
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. the UK Group for Immunoglobulin Replacement therapy in Multiple Myeloma
Conflicts between children
Clinical presentations in neuropsychiatry
Method of suturing a perforated ulcer of the stomach and duodenum
Identification of mechanical asphyxiation in cases of attempted masking of the homicide
Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Is it warm? Is it real? Or just low spatial frequency?
Additions and corrections to the list of Korean Heteroptera
Factors contributing to the maintenance of oligotrophy in an alpine glacial moraine lake (Wallowa lake) in Northeast Oregon
Classification, paleoecology, and biostratigraphy of crinoids from the Stull Shale (Late Pennsylvanian) of Nebraska, Kansas, and Iowa
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Neue Formen der Bauchsammler aus Turkmenien (Hymenoptera, Apoidea)
Atypische Hühnerpest und Newcastle-Krankheit. Ein Identifizierungsversuch
Parasitellus fucorum in the debris of Apis mellifera - a risk of confusion with Tropilaelaps spp
Applying the Technology Acceptance Model to the introduction of healthcare information systems
Ein akarologischer Nachruf für den "Roland"
Mutation research on crop plants in Argentina

No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease


No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease



International Journal for Vitamin and Nutrition Research. Internationale Zeitschrift für Vitamin- und Ernahrungsforschung. Journal International de Vitaminologie et de Nutrition 90(3-4): 279-289



ISSN/ISBN: 0300-9831

PMID: 30789808

Introduction: Cardiovascular disease (CVD) accounts as a major cause of mortality among patients with nonalcoholic fatty liver disease (NAFLD). Resveratrol, a natural polyphenol compound, is known for its antioxidant and antiatherogenic properties and is purported to be beneficial in decreasing CVD risk factors in NAFLD patients. Objectives: This study aimed to investigate the effects of resveratrol on atherogenic risk factors in patients with NAFLD. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed on 50 patients with NAFLD aged 20-60 years. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (n = 25) or placebo (n = 25) for 12 wk. Serum liver enzymes, lipid profile and atherogenic indices, blood pressure and anthropometric values were assessed pre and post-treatment. Results: Resveratrol supplementation reduced body weight (from 88.75 ± 11.41 to 87.54 ± 11.18 kg, P = 0.005) and BMI (from 31.00 ± 3.16 to 30.60 ± 3.26 kg/m², P = 0.01) significantly compared to the placebo group. A significant reduction in waist circumference was observed within resveratrol group (from 102.70 ± 7.68 to 101.39 ± 7.62 cm, P = 0.02). There were no significant changes in lipid profile (ox-LDL, ApoA1 and ApoB), serum atherogenic indices (LDL-C/HDL-C, ApoB/ApoA1, ox-LDL/ApoB, LDL-C/ox-LDL and AIP), liver enzymes (AST, ALT, ALP and GGT), hip circumference, waist-to-hip ratio and blood pressure in either group (P > 0.05 for all). Conclusion: These findings indicated that resveratrol supplementation in dose and duration used in this study did not affect most of the CVD risk factors in NAFLD patients. Further studies are warranted to explain more effects of resveratrol on CVD complications of NAFLD. Registration ID in IRCT: IRCT201511233664N16.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066517947

Download citation: RISBibTeXText

Related references

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. British Journal of Nutrition 114(5): 796-803, 2015

The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. References 33(9): 2369-2377, 2019

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology 40(8): 745-752, 2006

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutrition Research 34(10): 837-843, 2014

Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. Advanced Pharmaceutical Bulletin 8(2): 307-317, 2018

Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clinical Lipidology 6(3): 305-314, 2011

Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Archives of Medical Research 42(5): 337-353, 2011

Su1905 - Risk and Protective Factors for Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease in a Inflammatory Bowel Disease Patient Cohort. Gastroenterology 154(6): S-628, 2018

Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clinics in Liver Disease 22(1): 39-57, 2018

Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Nihon Shokakibyo Gakkai Zasshi 114(5): 813-818, 2017

Beneficial Effects of Insect Extracts on Nonalcoholic Fatty Liver Disease. Journal of Medicinal Food 23(7): 760-771, 2020

A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutrition Metabolism and Cardiovascular Diseases: Nmcd 25(8): 734-741, 2015

Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary and Pancreatic Diseases International: Hbpd Int 4(3): 389-392, 2005

Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease. Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft für Toxikologische Pathologie 64(4): 273-282, 2012

Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. Journal of the American College of Nutrition 37(3): 223-233, 2018